|
|
Chemin du Grand Puits 42, 1217 Meyrin
Geneva, Switzerland
phone:41 22 306 19 60
fax:+ 41 22 306 19 79
|
|
| Symbol |
Private |
| Founded |
2003 |
| Employees |
|
|
|
| www.endosense.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Catheter Ablation to treat Cardiac Arrhythmias |
|
| Management |
| Eric Le Royer, President & Chief Executive Officer; Giovanni Leo, Co-founder & Chief Technology Officer; Michael Grau, Chief Financial Officer; Eric Giroud, Director of Operations; Hendrik Lambert, Clinical and Regulatory Director |
| |
|
|
| |
|
| Keywords |
| atrial fibrillation, arrhythmias, ablation, force sensor, catheter |
|
|
|
| Description |
|
Endosense is a privately-held Swiss company focused on enabling the broad adoption of catheter ablation for the treatment of cardiac arrhythmias, including atrial fibrillation (AF). |
|
| Products / Services |
The TactiCath is the first force-sensing ablation catheter to provide physicians with a real-time, objective measure of contact force between the catheter and the beating heart wall, allowing electrophysiologists to deliver the appropriate force to the appropriate lesions.
|
|
| Technology / Differentiation |
| Endosense has pioneered the use of contact force measurement in catheter ablation. The company's proprietary fiber optic sensor technology, called Touch+, provides highly accurate and sensitive measurements at the catheter tip. The intuitive interface enables a physician to better control force amplitude and direction. |
|
| Market / Customers |
AF is currently the most common cardiac rhythm disorder, affecting more than six million people worldwide. Endosense is focused on providing this sizeable patient population with a minimally invasive treatment option that is both safe and effective. (Most AF patients are treated with ineffective and side effect-inducing pharmaceutical drugs, with the primary alternative being invasive ablation surgery.)
|
|
| Status |
| Endosense's TactiCath is currently being studied as part of TOCCATA (TOuCh+ for CATheter Ablation), a 76-patient, multi-center European clinical trial launched in September 2008. Results from TOCCATA, as well as extensive pre-clinical testing, have provided a solid foundation of evidence supporting the feasibility, safety and value of contact-force sensing during catheter ablation.
Endosense received the CE mark for its TactiCath force-sensing ablation catheter in May 2009. TactiCath is currently limited to investigational use only by the U.S. Food and Drug Administration. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members